전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,403 programs
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

B7-H3 CAR-T (B7-H3 CAR-T)

Recurrent Glioblastoma; Refractory Glioblastoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleStanford UniversityPhase 1

B7-H3CART (B7-H3CART)

Ovarian Cancer · B7-H3

#B7-H3#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleGuangzhou Bio-gene Technology C…Phase 1

BAFFR CAR-T (BAFFR CAR-T)

B Acute Lymphoblastic Leukemia/Lymphoma · B Acute Lymphoblastic Leukemia/Lymphoma

#BAcuteLymphoblasticLeukemiaLymph#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleSamsung Medical CenterPhase 2

durvalumab (Imfinzi, BAVC-C+Durvalumab)

Cervical Cancer · Cervical Cancer

#CervicalCancer#Antibody#Phase2#monoclonal-antibody#Samsung
Trials 1Status Active
AntibodyLimited DatastaleNavire Pharma Inc., a BridgeBio…Phase 1

nivolumab (Opdivo, BBP-398 with nivolumab)

Non Small Cell Lung Cancer; Solid Tumor · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase1#monoclonal-antibody#SolidTumor+1
Trials 1Status Discontinued
CGTLimited DatastaleZhejiang UniversityPhase 1

BCMA Targeted CAR T-cells (BCMA Targeted CAR T-cells)

Relapse Multiple Myeloma; Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleThe Pregene (ShenZhen) Biotechn…Phase 1

BCMA nanobody CAR-T cells (BCMA nanobody CAR-T cells)

Relapsed/Refractory Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 2

BCMA targeted prime CAR-T cells (BCMA targeted prime CAR-T cells)

Multiple Myeloma; Neoplasm, Plasma Cell · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastalePeking University People's Hosp…Phase 2

BCMA-CD19 CAR-T therapy (BCMA-CD19 CAR-T therapy)

Systemic Lupus Erythematosus; Inflammatory Myopathy · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

BCMA-CS1 cCAR T cells (BCMA-CS1 cCAR T cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleChinese PLA General HospitalPhase 2

BCMA-PD1-CART Cell (BCMA-PD1-CART Cell)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

0.50 x 10^6 cells/kg (BCMA-TGFβ CAR-T cells, BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

0.75 x10^6 cells/kg (BCMA-TGFβ CAR-T cells, BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

1 x 10^6 cells/kg (BCMA-TGFβ CAR-T cells, BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

2.5 x 10^6 cells/kg (BCMA-TGFβ CAR-T cells, BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleCells & Genes Biotech (Shanghai…Phase 1

BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell (BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell)

Relapsed/Refractory; Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBioray LaboratoriesPreclinical

BCMA-UCART (BCMA-UCART)

Multiple Myeloma · BCMA

#BCMA#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleHebei Yanda Ludaopei HospitalPhase 1

BCMA/CD19 dual-target CAR-T cell immunotherapy (BCMA/CD19 dual-target CAR-T cell immunotherapy)

Multiple Myeloma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleAllorunning TherapeuticsPhase 1

BCMA/CD19-targeted allogeneic CAR-T (BCMA/CD19-targeted allogeneic CAR-T)

Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT; Newly Diagnose… · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

BCMA/CD70-targetd CAR-T (BCMA/CD70-targetd CAR-T)

Juvenile Dermatomyositis (JDM); Polyarticular Juvenile Idiopathic Arthritis · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

53 / 121 pages

← PreviousNext →